Hutchinson-Gilford progeria syndrome (HGPS), commonly called progeria, is an 
extremely rare disorder that affects only one child per four million births. It 
is characterized by accelerated aging in affected individuals leading to 
premature death at an average age of 14.5 years due to cardiovascular 
complications. The main cause of HGPS is a sporadic autosomal dominant point 
mutation in LMNA gene resulting in differently spliced lamin A protein known as 
progerin. Accumulation of progerin under nuclear lamina and activation of its 
downstream effectors cause perturbation in cellular morphology and physiology 
which leads to a systemic disorder that mainly impairs the cardiovascular 
system, bones, skin, and overall growth. Till now, no cure has been found for 
this catastrophic disorder; however, several therapeutic strategies are under 
development. The current review focuses on the overall progress in the field of 
therapeutic approaches for the management/cure of HGPS. We have also discussed 
the new disease models that have been developed for the study of this rare 
disorder. Moreover, we have highlighted the therapeutic application of 
extracellular vesicles derived from stem cells against aging and aging-related 
disorders and, therefore, suggest the same for the treatment of HGPS.